All In Biotech

Drug Trial Radar · NCT06501573

A Study of SGB-9768 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Jul 18, 2024

Primary completion

May 7, 2026

Study completion May 7, 2026

Sponsor

Lead sponsor
Suzhou Sanegene Bio Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768 in healthy volunteers. The purpose is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768.

Conditions

  • Healthy Volunteer

Interventions

  • SGB-9768Drug

    SGB-9768 for sc injection

  • PlaceboOther

    sterile normal saline (0.9% NaCl) for sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SGB-9768Time frame: 169 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.